QuantSignals › Forecasts › THC
KATY's daily model path, its record on THC, and the options read. Prices as of the Nov 10, 2026 close · page updated Nov 10, 2026.
Last close
$290.27
Nov 10, 2026 · +0.44% on the day
KATY call
SELL
run Nov 6, 2026
Path end (20 sessions)
$235.31
−16.95% from $283.33
Path range
−16.9% to −1.2%
lowest and highest point of the path
Replay record on THC
4/15 hits
26.7% · 11 misses
Options
FAIR
IV 40% · 1.27× realized
KATY's latest public daily path for Tenet Healthcare, from its run on Nov 6, 2026, points down, which KATY labels SELL. Starting from the $283.33 close, the path ends 20 sessions later near $235.31 (−16.95%), around Dec 4, and ranges between −16.95% and −1.18% along the way. That is a model path, not a price target.
Since that run, THC has closed at $290.27 on Nov 10, 2026, +2.45% from the start, 2 of 20 sessions in. So far the move runs against the path. The call is scored after session 20.
On THC, KATY's replay record is 4 hits and 11 misses in 15 tested calls (26.7%), below its 50.1% rate across all tickers. Its most recent completed replay call expected −17.01% and THC moved +7.41%: a miss on direction.
In options, the at-the-money 2026-12-18 contract trades at 40% implied volatility against about 31% realized, 1.27× realized, so options read fairly priced. That is a pricing read, not a signal.
Daily closes, with KATY's Nov 6, 2026 path drawn from its start close to its end point; the shaded wedge spans the path's lowest and highest points.
The KATY apps and extension show the newest THC path as soon as it runs, with the full step-by-step line on the chart. They are free to install; live forecasts need KATY Premium or an FST membership.
Every public THC path this page has captured, scored on the close 20 sessions after its start: a BUY is a hit if that close is higher, a SELL if it is lower.
| Run | Call | Start close | Path end | Outcome at 20 sessions |
|---|---|---|---|---|
| Nov 6, 2026 | SELL | $283.33 | $235.31 (−16.95%) | Open, 2/20 sessions · +2.45% so far |
4 hits, 11 misses in 15 replayed THC calls (26.7% on direction; 20% finished inside the 1.5% band; average path error 14.1%). Across all tickers KATY's replay hit rate is 50.1% over 1,023 calls (BUY > +1.5%, SELL < -1.5% on the 20-step path). Replays re-run the model on past data it did not see; they are not live trades.
KATY re-forecast the 20 sessions that just finished without seeing them. It expected −17.01%; the actual move was +7.41% (direction miss, average path error 10.86%).
| Step | Session | Model path | Actual close | Path vs actual |
|---|---|---|---|---|
| 1 | Oct 12, 2026 | $259.62 | $268.76 | −3.40% |
| 5 | Oct 16, 2026 | $253.28 | $267.25 | −5.23% |
| 10 | Oct 23, 2026 | $243.14 | $268.45 | −9.43% |
| 15 | Oct 30, 2026 | $233.14 | $273.25 | −14.68% |
| 20 | Nov 6, 2026 | $218.91 | $283.33 | −22.74% |
The at-the-money 2026-12-18 THC option (38 days) is priced at 40.1% implied volatility, 1.27× the stock's realized volatility, which reads fair. Cheap or rich is a pricing read, not a signal. See the full options-value screen.
KATY's latest public daily path for THC (run Nov 6, 2026) is SELL: from $283.33 it ends near $235.31 (−16.95%) after 20 sessions. It is a model path, not a price target. The newest path is in the KATY apps (free to install; live forecasts need KATY Premium or an FST membership).
In replay, KATY called the direction of THC right 4 times and wrong 11 times out of 15 tested calls (26.7%). Public calls on this page are scored after 20 sessions and listed above, misses included.
KATY is a time-series foundation model that reads the recent daily bars of THC and draws the most likely path for the next 20 sessions. A path that ends more than 1.5% up is a BUY, more than 1.5% down a SELL, and anything in between is NEUTRAL. It is not investment advice.
KATY draws this forecast on your own charts: in TradingView with the Chrome extension, or on your phone. The extension and apps are free to install; live forecasts need KATY Premium or an FST membership.
Healthcare & biotech
Most viewed
Not investment advice. KATY's output is a model path, not a price target and not a recommendation to buy or sell. Model forecasts are often wrong; the hit and miss counts on this page are shown so you can judge that yourself. Trading involves risk of loss. Data from QS Research; prices are daily closes and may lag.